UMIN-CTR Clinical Trial

UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials


Recruitment status Terminated
Unique ID issued by UMIN UMIN000031424
Receipt No. R000035541
Scientific Title STroke secondary prevention with catheter ABLation and EDoxaban for patients with non-valvular atrial fibrillation
Date of disclosure of the study information 2018/03/01
Last modified on 2019/07/19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments

Basic information
Public title STroke secondary prevention with catheter ABLation and EDoxaban for patients with non-valvular atrial fibrillation
Acronym STroke secondary prevention with catheter ABLation and EDoxaban for patients with non-valvular atrial fibrillation: STABLED study
Scientific Title STroke secondary prevention with catheter ABLation and EDoxaban for patients with non-valvular atrial fibrillation
Scientific Title:Acronym STroke secondary prevention with catheter ABLation and EDoxaban for patients with non-valvular atrial fibrillation: STABLED study

Condition non-valvular atrial fibrillation
Classification by specialty
Cardiology Neurology Neurosurgery
Classification by malignancy Others
Genomic information NO

Narrative objectives1 To clarify efficacy and safety of catheter ablation added to anticoagulation therapy with Edoxaban in patients with non-valvular atrial fibrillation with a history of ischemic stroke in a multicenter cooperative prospective randomized comparative study.
In addition, we clarify factors influencing the discontinuation of Edoxaban and prognosis when it is discontinued for each non-valvular atrial fibrillation with or without catheter ablation.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Pragmatic
Developmental phase Phase IV

Primary outcomes The following composite events during observation period
1: Recurrence of ischemic stroke
2: Systemic embolism
3: All cause death
4: Hospitalization by Heart Failure
Key secondary outcomes <<Secondary Endpoints>>
1: Onset of stroke
2: Recurrence of ischemic stroke
3: Systemic embolism
4: All cause death
5: Cardiovascular death
6: Hospitalization by Heart Failure
7: Any bleeding
8: Onset of intracranial hemorrhage
9: Composite events (all cause death, onset of stroke, systemic embolism, hospitalization by Heart Failure, serious adverse event caused by catheter ablation)

<<The other Endpoints>>
1: Modified Rankin scale score and NYHA classification at the end of observation period
2: Maintenance rate of sinus rhythm
3: Changes in Mini-Mental State Examination (MMSE) scores during observation period
4: The continuation rate of Edoxaban
5: Recurrence rate of stroke according to whether or not Edoxaban discontinue
6: Factors which contribute to discontinue Edoxaban

Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control Active
Stratification YES
Dynamic allocation NO
Institution consideration Institution is not considered as adjustment factor.
Blocking YES
Concealment Central registration

No. of arms 2
Purpose of intervention Treatment
Type of intervention
Interventions/Control_1 Standard medication Group:
Anticoagulation therapy should be Edoxaban.
In addition, antiarrhythmic drugs are appropriately administered depending on the condition.
Dosage is according to the package insert of the drug to be used.
Interventions/Control_2 Catheter ablation additional Group:
Catheter ablation should be performed within 1 month to 6 months from the onset of ischemic stroke. Catheter ablation is based on pulmonary vein isolation and adds atrial ablation as needed.

Age-lower limit
20 years-old <=
Age-upper limit
80 years-old >=
Gender Male and Female
Key inclusion criteria 1) 20<=, 80> aged patients at the time of obtaining the informed consent
2) Patients with non-valvular atrial fibrillation
3) have a history of a prior stroke
within 6 months before enrolment
4) Patients who is being treated or will be treated with Edoxaban
5) Patients with modified Rankin Scale under 3
Key exclusion criteria 1) Patients who have symptomatic paroxysmal atrial fibrillation and drug resistant
2) Patients who have Left Atrial
Thrombus and left atrial appendage by transthoracic echocardiography,
Computed Tomography(CT),Magnetic Resonance Imaging(MRI)
3) Patients who have a tendency to bleed or bleed and are considered to be at high risk of bleeding due to anticoagulation therapy. For other reasons, patients who cannot conduct anticoagulation therapy
4) Patients who are suffering from severe renal disorder (Ccr*<30mL/min)
*Cockroft-Gault Equation
5) Patients who have undergone catheter ablation or surgical intervention for AF
6) Patients who have a treatment history with left atrial appendage closure device
7) Patients who have a left atrial diameter;55mm<= with transthoracic echocardiography
8) Patients who have ejection fraction;35%>= with transthoracic echocardiography
9) Persistent non-valvular atrial fibrillation over 10 years
10)Patients who have atrial septal defect
11) Patients who are pregnant and of child-bearing potential
12) Patients who are unlikely to complete research, such as progressive malignant tumor
13) Patients who is being participated or will be participated to other clinical trials
14) Patients who do not agree the study inclusion
15) Patients judged as inappropriate for this study by investigators
Target sample size 250

Research contact person
Name of lead principal investigator
1st name Kazumi
Middle name
Last name Kimura
Organization Nippon Medical School Hospital
Division name Department of Neurological Science
Zip code 113-8602
Address 1-1-5 Sendagi, Bunkyo-ku, Tokyo
TEL 03-3822-2131

Public contact
Name of contact person
1st name Kaoru
Middle name
Last name Okabe
Organization EP-CRSU Co.,Ltd
Division name Clinical Research Headquaters, Management Department 2 Section1
Zip code 162-0814
Address Acropolis TOKYO Bldg., 6-29 Shinogawamachi, Shinjuku-ku, Tokyo
TEL 03-5804-5045
Homepage URL

Institute Nippon Medical School Hospital

Funding Source
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Name of secondary funder(s)

IRB Contact (For public release)
Organization Institutional Review Board of Nippon Medical School Foundation
Address 1-1-5 Sendagi, Bunkyo-ku, Tokyo
Tel 03-5802-8202

Secondary IDs
Secondary IDs YES
Study ID_1 jRCTs031180249
Org. issuing International ID_1 jRCT
Study ID_2
Org. issuing International ID_2


Other administrative information
Date of disclosure of the study information
2018 Year 03 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

URL related to results and publications
Number of participants that the trial has enrolled
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Recruitment status Terminated
Date of protocol fixation
2018 Year 01 Month 05 Day
Date of IRB
2018 Year 02 Month 28 Day
Anticipated trial start date
2018 Year 03 Month 01 Day
Last follow-up date
2021 Year 02 Month 28 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other related information

Management information
Registered date
2018 Year 02 Month 22 Day
Last modified on
2019 Year 07 Month 19 Day

Link to view the page

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name

Contact us.